32,667 Shares in IO Biotech, Inc. (NASDAQ:IOBT) Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. bought a new position in IO Biotech, Inc. (NASDAQ:IOBT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 32,667 shares of the company’s stock, valued at approximately $30,000.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of IO Biotech in a report on Tuesday, November 12th.

IO Biotech Stock Down 0.9 %

Shares of IOBT opened at $1.10 on Friday. IO Biotech, Inc. has a 52-week low of $0.66 and a 52-week high of $1.85. The company has a market capitalization of $72.47 million, a PE ratio of -0.80 and a beta of 0.24. The stock has a fifty day simple moving average of $0.90 and a two-hundred day simple moving average of $1.04.

IO Biotech Profile

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.